Literature DB >> 31044239

Quantitative RyR1 reduction and loss of calcium sensitivity of RyR1Q1970fsX16+A4329D cause cores and loss of muscle strength.

Moran Elbaz1, Alexis Ruiz1, Christoph Bachmann1, Jan Eckhardt1, Pawel Pelczar2, Elisa Venturi3, Chris Lindsay3,4, Abigail D Wilson3, Ahmed Alhussni3, Thomas Humberstone3, Laura Pietrangelo5, Simona Boncompagni5, Rebecca Sitsapesan3, Susan Treves1,6, Francesco Zorzato1,6.   

Abstract

Recessive ryanodine receptor 1 (RYR1) mutations cause congenital myopathies including multiminicore disease (MmD), congenital fiber-type disproportion and centronuclear myopathy. We created a mouse model knocked-in for the Q1970fsX16+A4329D RYR1 mutations, which are isogenic with those identified in a severely affected child with MmD. During the first 20 weeks after birth the body weight and the spontaneous running distance of the mutant mice were 20% and 50% lower compared to wild-type littermates. Skeletal muscles from mutant mice contained 'cores' characterized by severe myofibrillar disorganization associated with misplacement of mitochondria. Furthermore, their muscles developed less force and had smaller electrically evoked calcium transients. Mutant RyR1 channels incorporated into lipid bilayers were less sensitive to calcium and caffeine, but no change in single-channel conductance was observed. Our results demonstrate that the phenotype of the RyR1Q1970fsX16+A4329D compound heterozygous mice recapitulates the clinical picture of multiminicore patients and provide evidence of the molecular mechanisms responsible for skeletal muscle defects.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31044239     DOI: 10.1093/hmg/ddz092

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  11 in total

1.  Bi-allelic expression of the RyR1 p.A4329D mutation decreases muscle strength in slow-twitch muscles in mice.

Authors:  Moran Elbaz; Alexis Ruiz; Sven Nicolay; Chiara Tupini; Christoph Bachmann; Jan Eckhardt; Sofia Benucci; Pawel Pelczar; Susan Treves; Francesco Zorzato
Journal:  J Biol Chem       Date:  2020-06-04       Impact factor: 5.157

Review 2.  Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.

Authors:  Tokunbor A Lawal; Emily S Wires; Nancy L Terry; James J Dowling; Joshua J Todd
Journal:  Orphanet J Rare Dis       Date:  2020-05-07       Impact factor: 4.123

Review 3.  Cored in the act: the use of models to understand core myopathies.

Authors:  Aurora Fusto; Louise A Moyle; Penney M Gilbert; Elena Pegoraro
Journal:  Dis Model Mech       Date:  2019-12-19       Impact factor: 5.758

Review 4.  Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.

Authors:  Tokunbor A Lawal; Joshua J Todd; Jessica W Witherspoon; Carsten G Bönnemann; James J Dowling; Susan L Hamilton; Katherine G Meilleur; Robert T Dirksen
Journal:  Skelet Muscle       Date:  2020-11-16       Impact factor: 4.912

Review 5.  From Mice to Humans: An Overview of the Potentials and Limitations of Current Transgenic Mouse Models of Major Muscular Dystrophies and Congenital Myopathies.

Authors:  Mónika Sztretye; László Szabó; Nóra Dobrosi; János Fodor; Péter Szentesi; János Almássy; Zsuzsanna É Magyar; Beatrix Dienes; László Csernoch
Journal:  Int J Mol Sci       Date:  2020-11-25       Impact factor: 5.923

Review 6.  Common Pathogenic Mechanisms in Centronuclear and Myotubular Myopathies and Latest Treatment Advances.

Authors:  Raquel Gómez-Oca; Belinda S Cowling; Jocelyn Laporte
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

7.  Improvement of muscle strength in a mouse model for congenital myopathy treated with HDAC and DNA methyltransferase inhibitors.

Authors:  Alexis Ruiz; Sofia Benucci; Urs Duthaler; Christoph Bachmann; Martina Franchini; Faiza Noreen; Laura Pietrangelo; Feliciano Protasi; Susan Treves; Francesco Zorzato
Journal:  Elife       Date:  2022-03-03       Impact factor: 8.140

8.  Identification of drug modifiers for RYR1-related myopathy using a multi-species discovery pipeline.

Authors:  Jonathan R Volpatti; Yukari Endo; Jessica Knox; Linda Groom; Stephanie Brennan; Ramil Noche; William J Zuercher; Peter Roy; Robert T Dirksen; James J Dowling
Journal:  Elife       Date:  2020-03-30       Impact factor: 8.140

9.  Interactions among ryanodine receptor isotypes contribute to muscle fiber type development and function.

Authors:  Alexis A Chagovetz; Dana Klatt Shaw; Erin Ritchie; Kazuyuki Hoshijima; David J Grunwald
Journal:  Dis Model Mech       Date:  2019-09-18       Impact factor: 5.758

10.  In vivo RyR1 reduction in muscle triggers a core-like myopathy.

Authors:  Laurent Pelletier; Anne Petiot; Julie Brocard; Benoit Giannesini; Diane Giovannini; Colline Sanchez; Lauriane Travard; Mathilde Chivet; Mathilde Beaufils; Candice Kutchukian; David Bendahan; Daniel Metzger; Clara Franzini Armstrong; Norma B Romero; John Rendu; Vincent Jacquemond; Julien Fauré; Isabelle Marty
Journal:  Acta Neuropathol Commun       Date:  2020-11-11       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.